Standard BioTools Inc. (LAB) vs TriSalus Life Sciences, Inc. (TLSI)

Standard BioTools Inc. and TriSalus Life Sciences, Inc. are both Medical Devices companies. Standard BioTools Inc. and TriSalus Life Sciences, Inc. are of similar size ($303.6M and $291.7M). TriSalus Life Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Standard BioTools Inc. trades at 3.4×. Standard BioTools Inc. grew revenue faster over the last twelve months: 30.2% against 25.3%. Standard BioTools Inc. has the higher net margin (100.4% vs −127.0%) and the lower return on invested capital (−93.9% vs 0.00%). Across the 17 metrics below, Standard BioTools Inc. leads on 10 and TriSalus Life Sciences, Inc. on 7.

Valuation

Metric LAB TLSI Medical Devices median
P/E 3.36 n/m 22.18
P/S 3.42 5.61 2.70
P/B 0.54 38.63 2.46
Price to free cash flow n/m n/m 22.53
EV/EBITDA 1.96 n/m 11.78
EV/Sales (2.15) 5.33 2.38
Earnings yield 29.73% (29.95%) (8.22%)
Free cash flow yield (30.83%) (9.48%) (7.80%)

Profitability

Metric LAB TLSI Medical Devices median
Gross margin 50.49% 85.79% 56.01%
Operating margin (112.85%) (67.68%) (15.03%)
Net margin 100.37% (127.00%) (20.40%)
Free cash flow margin (97.61%) (51.56%) (7.24%)
Return on equity 17.61% 889.44% (15.32%)
Return on assets 14.34% (110.34%) (19.72%)
Return on invested capital (93.89%) 0.00% (10.33%)

Growth

Metric LAB TLSI Medical Devices median
Revenue growth (TTM) 30.23% 25.25% 8.80%
EPS growth (last fiscal year) 61.54% (40.46%) —
Revenue growth, 5-year CAGR (9.19%) — 15.23%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LAB TLSI Medical Devices median
Debt to equity 0.00 5.05 0.07
Current ratio 9.10 5.35 2.50
Net debt to EBITDA 1.84 (0.50) 0.49

Dividend

Metric LAB TLSI Medical Devices median
Dividend yield — — 0.94%
Payout ratio 0.00 0.00 0.00

Size

Metric LAB TLSI Medical Devices median
Market cap 291.69m 303.56m 172.91m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack